Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024.
This follows the earlier notification on October 11, 2024, when the facility was assigned Official Action Indicated (OAI) status. The USFDA’s concerns, detailed in the warning letter issued on December 17, 2024, address non-compliance with Current Good Manufacturing Practices (CGMP).
The company remains committed to resolving these issues promptly and continues to collaborate with the USFDA to address the concerns. Indoco emphasizes its dedication to upholding high standards of quality and compliance across all its facilities. Despite the warning, production continues at the Goa facility to meet customer and patient needs in the United States.
In the meantime, Indoco Remedies shares dropped 6.64% after the update, trading at Rs 317.95. The shares opened today at ₹341.00, reaching a high of ₹341.00 and a low of ₹313.85 during the session. The stock’s 52-week high stands at ₹415.00, while its 52-week low is ₹286.60.
